Data Insights

Emraclidine by Cerevel Therapeutics for Dementia Associated With Alzheimer's Disease: Likelihood of Approval

Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase I for Dementia Associated With Alzheimer's Disease. According...

Likelihood of Approval and Phase Transition Success Rate Model - Emraclidine in Dementia Associated With Alzheimer's Disease

Data Insights

Darigabat by Cerevel Therapeutics for Seizures: Likelihood of Approval

Darigabat is under clinical development by Cerevel Therapeutics and currently in Phase II for Seizures. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Darigabat in Seizures

Data Insights

Razpipadon by Cerevel Therapeutics for Dementia: Likelihood of Approval

Razpipadon is under clinical development by Cerevel Therapeutics and currently in Phase II for Dementia. According to GlobalData, Phase II...

Likelihood of Approval and Phase Transition Success Rate Model - Razpipadon in Dementia

Data Insights

Emraclidine by Cerevel Therapeutics for Psychosis: Likelihood of Approval

Emraclidine is under clinical development by Cerevel Therapeutics and currently in Phase II for Psychosis. According to GlobalData, Phase II...

Data Insights

Icalcaprant by Cerevel Therapeutics for Bipolar I Disorder: Likelihood of Approval

Icalcaprant is under clinical development by Cerevel Therapeutics and currently in Phase I for Bipolar I Disorder. According to GlobalData,...

Data Insights

Tavapadon by Cerevel Therapeutics for Parkinson's Disease: Likelihood of Approval

Tavapadon is under clinical development by Cerevel Therapeutics and currently in Phase III for Parkinson's Disease. According to GlobalData, Phase...

Likelihood of Approval and Phase Transition Success Rate Model - Tavapadon in Parkinson's Disease